Bharat Book Bureau: Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022
(M2 PressWIRE Via Acquire Media NewsEdge) Summary
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics.
Sofosbuvir, previously known as GS-7977, is an HCV therapy being developed by Gilead, which obtained the rights to the drug through its acquisition of Pharmasset in November of 2011. As an NS5B nucleotide polymerase inhibitor, sofosbuvir exhorts its antiviral activity by mimicking the natural substrate of the viral RNA-dependent RNA polymerase.
- Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Sofosbuvir and Sofosbuvir/Ledipasvir including product description, safety and efficacy profiles as well as a SWOT analysis.
For more information visit : http://www.bharatbook.com/healthcare-market-research-reports/sofosbuvir-and-sofosbuvir-ledipasvir-hepatitis-c-virus-forecast-and-market-analysis-to-20221.html
Contact us at :
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
For live chat : http://bit.ly/19m3TU4
Follow us on twitter: https://twitter.com/researchbook
Follow us on linkedin : http://www.linkedin.com/company/bharat-book-bureau
Our Blog : http://blog.bharatbook.com/
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to email@example.com)).
(c) 2013 M2 COMMUNICATIONS
[ InfoTech Spotlight's Homepage ]